losartan-potassium and Genetic-Diseases--Inborn

losartan-potassium has been researched along with Genetic-Diseases--Inborn* in 2 studies

Reviews

1 review(s) available for losartan-potassium and Genetic-Diseases--Inborn

ArticleYear
Genetic causes of erythrocytosis and the oxygen-sensing pathway.
    Blood reviews, 2008, Volume: 22, Issue:6

    Idiopathic erythrocytosis is an uncommon disease, and is defined by an increase in red blood cell mass. The differential diagnosis of erythrocytosis is extensive, and can be divided into primary and secondary forms. Primary erythrocytoses are due to intrinsic defects in erythroid precursor cells and are characterized by low erythropoietin levels. Secondary erythrocytoses are extrinsic to erythroid progenitors and are characterized by either high or inappropriately normal erythropoietin levels. A distinct subset of secondary erythrocytoses are due to genetic mutations in key proteins of the oxygen-sensing pathway. These proteins constitute the core molecular machinery of oxygen-sensing with respect to red blood cell control. Apart from assigning physiologic roles for these proteins, studies of these rare mutations have (i) revealed the exquisite sensitivity of this pathway to genetic perturbations, (ii) highlighted important functional regions of the proteins, and (iii) provided a basis for potentially targeting this pathway for therapeutic benefit.

    Topics: Erythroid Precursor Cells; Erythropoietin; Genetic Diseases, Inborn; Humans; Mutation; Oxygen; Polycythemia

2008

Other Studies

1 other study(ies) available for losartan-potassium and Genetic-Diseases--Inborn

ArticleYear
von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.
    The Journal of clinical investigation, 2007, Volume: 117, Issue:12

    The R200W mutation in the von Hippel-Lindau (VHL) tumor suppressor protein (pVHL) is unique in that it is not associated with tumor development, but rather with Chuvash polycythemia, a heritable disease characterized by elevated hematocrit and increased serum levels of erythropoietin and VEGF. Previous studies have implicated hypoxia-inducible factor-1alpha (HIF-1alpha) signaling in this disorder, although the effects of this mutation on pVHL function are not fully understood. In order to explore the mechanisms underlying the development of this polycythemia, we generated mice homozygous for the R200W mutation (Vhl(R/R)). Vhl(R/R) mice developed polycythemia highly similar to the human disease. The activity of HIF proteins, specifically the HIF-2alpha isoform, was upregulated in ES cells and tissues from Vhl(R/R) mice. Furthermore, we observed a striking phenotype in Vhl(R/R) spleens, with greater numbers of erythroid progenitors and megakaryocytes and increased erythroid differentiation of Vhl(R/R) splenic cells in vitro. These findings suggest that enhanced expression of key HIF-2alpha genes promotes splenic erythropoiesis, resulting in the development of polycythemia in Vhl(R/R) mice. This mouse model is a faithful recapitulation of this VHL-associated syndrome and represents a useful tool for studying polycythemias and investigating potential therapeutics.

    Topics: Amino Acid Substitution; Animals; Basic Helix-Loop-Helix Transcription Factors; Disease Models, Animal; Erythropoiesis; Erythropoietin; Genetic Diseases, Inborn; Hematopoiesis, Extramedullary; Humans; Megakaryocytes; Mice; Mice, Mutant Strains; Mutation, Missense; Polycythemia; Signal Transduction; Spleen; Vascular Endothelial Growth Factors; Von Hippel-Lindau Tumor Suppressor Protein

2007